Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.
复制标题
由特异性干扰素刺激的内源性逆转录病毒引发的肿瘤固有免疫。
DOI:
10.1038/s41591-018-0116-5
复制
发表时间:
2018-08
期刊:
影响因子:
82.9
通讯作者:
Barbie DA
中科院分区:
文献类型:
--
作者:
Cañadas I;Thummalapalli R;Kim JW;Kitajima S;Jenkins RW;Christensen CL;Campisi M;Kuang Y;Zhang Y;Gjini E;Zhang G;Tian T;Sen DR;Miao D;Imamura Y;Thai T;Piel B;Terai H;Aref AR;Hagan T;Koyama S;Watanabe M;Baba H;Adeni AE;Lydon CA;Tamayo P;Wei Z;Herlyn M;Barbie TU;Uppaluri R;Sholl LM;Sicinska E;Sands J;Rodig S;Wong KK;Paweletz CP;Watanabe H;Barbie DA
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance. This phenomenon has been implicated in chemorefractory small cell lung cancer (SCLC) and resistance to targeted therapies, but remains incompletely defined. Here we identify a subclass of endogenous retroviruses (ERVs) that engages innate immune signaling in these cells. Stimulated 3 Prime Antisense Retroviral Coding Sequences (SPARCS) are oriented inversely in 3′UTRs of specific genes enriched for regulation by STAT1 and EZH2. De-repression of these loci results in dsRNA generation following IFNγ exposure due to bi-directional transcription from the STAT1-activated gene promoter and the 5′ LTR of the antisense ERV. Engagement of MAVS and STING activates downstream TBK1, IRF3, and STAT1 signaling, sustaining a positive feedback loop. SPARCS induction in human tumors is tightly associated with MHC class 1 expression, mesenchymal markers, and downregulation of chromatin modifying enzymes, including EZH2. Analysis of cell lines with high inducible SPARCS expression reveals strong association with an AXL/MET positive mesenchymal cell state. While SPARCS high tumors are immune infiltrated, they also exhibit multiple features of an immune suppressed microenviroment. Together, these data unveil a subclass of ERVs whose de-repression triggers pathologic innate immune signaling in cancer, with important implications for cancer immunotherapy.
登录
查看更多内容
影响因子:
64.8
作者:
Manguso RT;Pope HW;Zimmer MD;Brown FD;Yates KB;Miller BC;Collins NB;Bi K;LaFleur MW;Juneja VR;Weiss SA;Lo J;Fisher DE;Miao D;Van Allen E;Root DE;Sharpe AH;Doench JG;Haining WN
通讯作者:
Haining WN
影响因子:
46.9
作者:
Doench JG;Fusi N;Sullender M;Hegde M;Vaimberg EW;Donovan KF;Smith I;Tothova Z;Wilen C;Orchard R;Virgin HW;Listgarten J;Root DE
通讯作者:
Root DE
影响因子:
64.8
作者:
Marusyk, Andriy;Tabassum, Doris P.;Altrock, Philipp M.;Almendro, Vanessa;Michor, Franziska;Polyak, Kornelia
通讯作者:
Polyak, Kornelia
DOI:
10.1126/science.aan5951
发表时间:
2018-02-16
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Miao D;Margolis CA;Gao W;Voss MH;Li W;Martini DJ;Norton C;Bossé D;Wankowicz SM;Cullen D;Horak C;Wind-Rotolo M;Tracy A;Giannakis M;Hodi FS;Drake CG;Ball MW;Allaf ME;Snyder A;Hellmann MD;Ho T;Motzer RJ;Signoretti S;Kaelin WG Jr;Choueiri TK;Van Allen EM
通讯作者:
Van Allen EM
DOI:
10.1126/science.aad5497
发表时间:
2016-03-04
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Chuong EB;Elde NC;Feschotte C
通讯作者:
Feschotte C